Mechanistic target of rapamycin inhibitors in solid organ transplantation: From benchside to clinical use

Current Opinion in Organ Transplantation

Volumn 17, Issue 6, 2012, Pages 626-633

  Touzot, Maxime ^a   Soulillou, Jean Paul ^a   Dantal, Jacques ^a  

^a Centre National de la Recherche Scientifique   (France)

Author keywords

everolimus; mTOR; organ transplantation; signaling pathway; sirolimus

Indexed keywords

ANTIANEMIC AGENT; CALCINEURIN INHIBITOR; CD8 ANTIGEN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS;

ANGIONEUROTIC EDEMA; BIOLOGICAL FUNCTIONS; CANCER PREVENTION; CANCER RISK; CD8+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CYTOPENIA; DENDRITIC CELL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HELPER CELL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPOGENESIS; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCELE; MUCOSAL DISEASE; NEOPLASM; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PODOCYTE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEIN SYNTHESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; SYSTEMATIC REVIEW; WOUND COMPLICATION;

CALCINEURIN; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, HELPER-INDUCER; TOR SERINE-THREONINE KINASES;

EID: 84870245978     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835a4be2     Document Type: Review

References (114)

1. Zoncu R, Efeyan A, Sabatini D. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 1:21-35.
2. Wullschleger S, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell 2006; 124:471-484. (Pubitemid 43199434)
3. Yip C, Murata K, Walz T, et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cel 2010; 38:768-774.
4. Sancak Y, Peterson T, Shaul Y, et al. The rag GTPases bind RAPTOR and mediate amino acid signaling to mTORC1. Science 2008; 320:1496-1501. (Pubitemid 351929429)
5. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002; 4:648-657. (Pubitemid 34993700)
6. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signalling. Science 2011; 332:1317-1322.
7. Laplante M, Sabatini D. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009; 19:1046-1052.
8. Settembre C, Zoncu R, Medina D, et al. A lysosome-to-nucleus signaling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO 2012; 31:1095-1108.
9. Garcia-Martinez J, Alessi D. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008; 416:375-385.
10. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-1128. (Pubitemid 39468014)
11. Yang C, Song C, Lee J, et al. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages. Cell Microbiol 2006; 8:1158-1171. (Pubitemid 43871650)
12. Cao W, Manicassamy S, Tang H, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008; 9:1157-1164.
13. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signalling pathway regulates the innate inflammatory response. Immunity 2008; 29:565-577.
14. Kudchodkar S, Yu U, Maguire T, et al. Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of RAPTOR- and RICTOR-containing complexes. Proc Natl Acad Sci USA 2006; 103:14182-14187. (Pubitemid 44453000)
15. Moorman N, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84:5260-5269.
16. Buchkovich N, Yu Y, Zampieri C, et al. The TORrid affairs of virus: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signaling pathway. Nat Rev Microbiol 2008; 4:266-275.
17. Kudchodkar S, Yu U, Maguire TG, et al. Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinases. J Virol 2004; 78:11030-11039. (Pubitemid 39299643)
18. Shi L, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of Th17 and Treg cells. J Exp Med 2011; 7:1367-1376.
19. Katzman S, O'Gorman W, Villarino A. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc Natl Acad Sci USA 2010; 107:18085-18090.
20. Delgoffe G, Kole T, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30:832-844.
21. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 5:324-337.
22. Yang K, Neale G, Green D, et al. The tumor suppressor TSC1 enforces quiescence ofnaive T cells to promote immune homeostasis and function. Nat Immunol 2011; 12:888-897.
23. Gulen M, Kang Z, Bulek K, et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010; 32:54-66.
24. Delgoffe G, Pollizzi K, Waickman A, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signalling by mTORC1 and mTORC2. Nat Immunol 2011; 4:295-303.
25. Battaglia M, Stabilini A, Tresoldi E. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol 2012; 821:279-293.
26. Brouard S, Puig-Pey I, Lozano J, et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidneys recipients under cyclosporine A or sirolimus monotherapy. Am J Transplant 2010; 12:2604-2614.
27. Araki K, Turner A, Shaffer V, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-112.
28. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2011; 235:234-243.
29. Sinclair L, Finlay D, Feijoo C, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008; 9:513-521. (Pubitemid 351560520)
30. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121:2181-2196.
31. Huber T, Walz G, Kuehn E. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011; 79:502-511.
32. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121:2197-2209.
33. Vollenbroken B, George B, Wolfgart M, et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009; 296:418-426.
34. Cina D, Onay T, Paltoo A, et al. Inhibition of mTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 2012; 23:412-420.
35. Schena F, Pascoe M, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-months efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233-242.
36. Aliabadi A, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008; 8:854-861. (Pubitemid 351347752)
37. Vuiblet V, Birembaut P, François A, et al. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephro Dial Transplant 2012; 27:411-416.
38. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:830-910.
39. Serra A, Poster D, Kistler A, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363:820-829.
40. Lorber M, Pontielli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005; 19:145-152. (Pubitemid 40424882)
41. Kahan B, Napoli K, Kelly P, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14:97-109. (Pubitemid 30171208)
42. Eisen H, Tuzcu E, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplants recipients. N Engl J Med 2003; 349:847-858. (Pubitemid 37025404)
43. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years; a randomized clinical trial. Circulation 2004; 110:2694-2700. (Pubitemid 39453021)
44. Lehmkuhl H, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 15:115-122.
45. Calmus Y, Durrbach A. Everolimus de novo in liver transplantation. Gastroenterol Clin Biol 2009; 33:S247-S252.
46. Massoud O, Wiesner R. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012; 56:288-290.
47. Bhorade S, Ahra V, Baz M, et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011; 183:379-387.
48. Srinivas T, Schold J, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7:586-594. (Pubitemid 46376441)
49. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med 2007; 357:2562-2575. (Pubitemid 350294223)
50. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after decreased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88:69-76.
51. Pengel l, Liu L, Morris P. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transplant Int 2011; 24:1216-1230.
52. Flechner S, Glyda M, Cockfield S, et al. The ORION study: comparison to two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11:1633-1644.
53. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7:2522-2531. (Pubitemid 47561618)
54. Larson T, Dean P, Stegall M, et al. Complete avoidance of calcineurin inhibitors in renal transplantation. Am J Transplant 2006; 6:514-522.
55. Mulay A, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153-1162. (Pubitemid 44748017)
56. Weir M, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2010; 79:897-907.
57. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor free regimen in recipients of de novo kidney transplants; an open-label, randomised, controlled trial. Lancet 2011; 377:837-847.
58. Lebranchu Y, Snanoudj R, Toupance O, et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the Spiesser study. Am J Transplant 2012; 12:1801-1810.
59. Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF: four-year results of the postconcept study. Am J Transplant 2011; 11:1665-1675.
60. Pontrelli P, Rossini M, Infante B, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85:125-134.
61. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12:1192-1198.
62. Croze E, Tetaz R, Malvezzi P, et al. mTOR inhibitors and humoral immunity: a dangerous liaison? Am J Transplant 2012; 42 (Suppl 3): (abstract 54).
63. Holdass H, Rostaing L, Seron D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24 month study. Transplantation 2011; 92:410-418.
64. Zuckermann A, Keogh A, Crespo-Leiro M, et al. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant 2012; 12:2487-2497.
65. Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation 2012; 125:708-720.
66. Wadei H, Zaky Z, Keaveny A, et al. Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients. Transplantation 2012; 93:1006-1012.
67. Abdelmalek M, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12:694-705.
68. Tedesco-Silva H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10:1401-1413.
69. Salvadori M, Scolari M, Bertoni E, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88:1194-1202.
70. Arora S, Gude E, Sigurdardottir V, et al. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012; 31:259-265.
71. Cianco G, Burke G, Gaynor J, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77:224-251.
72. Meier-Kriesche H, Schold J, Srinivas T, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5:2273-2280. (Pubitemid 41648476)
73. Chan L, Greenstein S, Hardy M, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85:821-826. (Pubitemid 351440746)
74. Langer R, Hene R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant Int 2012; 25:592-602.
75. Sampaio M, Cho Y, Shah T, et al. Association of immunosuppressive maintenance regimens with post transplant lymphoproliferative disorders in kidney transplant recipients. Transplantation 2012; 93:73-81.
76. Campistol J, de Fijter H, Flechner S, et al. mTOR inhibitors-associated dermatologic and mucosal problems. Clin Transplant 2010; 24:149-156.
77. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduces fertility in male renal transplant recipients. Am J Transplant 2008; 8:1471-1479. (Pubitemid 351989493)
78. Rovira J, Diekmann F, Ramirez-Bajo M, et al. Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation 2012; 93:874-879.
79. Sanchez-Fructuoso A, Ruiz J, Perz-Flores I, et al. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus Sirolimus. Transplant Proc 2010; 42:3050-3052.
80. Tedesco-Silva H, Irish W, Kim Y, et al. Impact of everolimus-based immunosuppression on graft survival following kidney transplantation. Am J Transplant 2012, 408 (Suppl 3): (abstract 1296)
81. Cortazar F, Molnar M, Isakova T, et al. Clinical outcome in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2012; 12:379-387.
82. Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012; 12:1458-1468.
83. Clippinger A, Maguire T, Alwine J. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85:3930-3939.
84. + T cell responses. J Immunol 2010; 185:2004-2008.
85. Fortun J, Martin-Dasilva P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transplant Infect Dis 2010; 12:397-405.
86. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection finding with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93:1075-1085.
87. Vigano M, Dengler T, Mattei M, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 2010; 12:23-30.
88. Brennan D, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Transplantation 2011; 11:2453-2462.
89. Benavides C, Pollard V, Mauiyyedi S, et al. BK virus associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84:83-88. (Pubitemid 47094646)
90. Schwarz A, Linnenweber-Held S, Heim A, et al. Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation 2012; 94 [Epub ahead of print].
91. Ozaki K, Camara N, Nogueira E, et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21:675-680. (Pubitemid 47399434)
92. Raichlin E, Bae J, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007; 116:2726-2733. (Pubitemid 350291245)
93. Eisen H. Long term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3): iii 9-13.
94. Paoletti E, Marsano L, Bellino D, et al. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 2012; 93:503-508.
95. Joannides R, Monteil C, De Ligny B, et al. Immunosupressant regimen based on sirolimus decrease aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 2011; 11:2414-2422.
96. Seckinger J, Sommerer C, Hinkel U, et al. Switch of immunosuppression from cyclosporine A to everolimus; impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26:2213-2219.
97. Servais A, Meas-Yedid V, Toupance O, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9:2552-2560.
98. Heilman R, Cortese C, Geiger X, et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation 2012; 93:47-53.
99. Gelens M, Steegh S, van Hoof J, et al. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant. Clin J Am Soc Nephrol 2012; 7:1010-1017.
100. McKenna G, Trotter J, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11:2379-2387.
101. Hiemann N, Wellnhofer E, Lehmkuhl H, et al. Everolimus prevents endomyocardial remodelling after heart transplantation. Transplantation 2011; 92:1165-1172.
102. Kahan B, Yakupoglu Y, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749-758. (Pubitemid 41443756)
103. Kauffman H, Cherikh W, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889. (Pubitemid 41552882)
104. Mathew T, Kreis H, Friend P, et al. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from the five multicenter studies. Clin Transplant 2004; 18:446-449. (Pubitemid 39077081)
105. Campistol J, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-589.
106. Alberu J, Pascoe M, Campistol J, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92:303-310.
107. Campbell S, Walker R, See Tai S, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12:1146-1156.
108. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367:329-339.
109. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317-1323. (Pubitemid 40411498)
110. Pascual J. Post transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22:27-31.
111. Fergusson R, Grinyo J, Vincenti F, et al. Immunosuppression with Belatacept-based corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:66-76.
112. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukaemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 10:205-213.
113. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-3074.
114. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 12:1351-1356.